TY - JOUR
T1 - Pharmaceutical opioid poisonings in Victoria, Australia
T2 - Rates and characteristics of a decade of emergency department presentations among nine pharmaceutical opioids
AU - Lam, Tina
AU - Hayman, Jane
AU - Berecki-Gisolf, Janneke
AU - Sanfilippo, Paul
AU - Lubman, Dan I.
AU - Nielsen, Suzanne
N1 - Funding Information:
This study is supported by an untied educational grant from Seqirus, who are the Australian distributors of Palexia® (tapentadol) and Tramal® (tramadol). The study was funded by an untied educational grant from Seqirus. S.N. is the recipient of an NHMRC Career Development Fellowship (no. 1163961). D.L. is supported by an NHMRC Leadership Fellowship (no. 1196892). The funders have no role in the study design, study conduct, analysis or data interpretation. Prior to publication, Seqirus will have the opportunity to review the manuscript and provide comment on factual inaccuracies, if identified. The Victorian Injury Surveillance Unit (VISU) are supported by the Victorian Government. The authors acknowledge the Victorian Agency for Health Information for providing data from the Victorian Emergency Minimum Dataset (VEMD).
Funding Information:
During the past 5 years, S.N. has been an investigator on untied education grants from Indivior, unrelated to the current work. S.N. has provided training to health‐care professionals on identifying and treating codeine dependence, for which her institution has received honoraria from Indivior. D.L. has received speaking honoraria from the following: Astra Zeneca, Indivior, Janssen‐Cilag, Lundbeck, Servier and Shire, and has participated on Advisory Boards for Indivior and Lundbeck. T.L., S.N. and D.L. have been investigators on an untied education grant from Seqirus. The Victorian Injury Surveillance Unit (VISU) is supported by the Victorian Government.
Publisher Copyright:
© 2021 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2022/3
Y1 - 2022/3
N2 - Background and aims: Pharmaceutical opioids are a significant contributor to the global ‘opioid crisis’, yet few studies have comprehensively distinguished between opioid types. We measured whether a range of common pharmaceutical opioids varied in their contribution to the rates and characteristics of harm in a population-wide indicator of non-fatal overdose. Design: Retrospective observational study of emergency department (ED) patient care records in the Victorian Emergency Minimum Data set (VEMD), July 2009 to June 2019. Setting: Victoria, Australia. Cases: ED presentations for non-fatal overdose related to pharmaceutical opioid use (n = 5403), where the specific pharmaceutical opioid was documented. Measurements: We compared harms across the nine individual pharmaceutical opioids most commonly sold, and considered where multiple opioids contributed to the overdose. We calculated supply-adjusted rates of ED presentations using Poisson regression and used multinomial logistic regression to compare demographic and clinical characteristics of presentations among nine distinct pharmaceutical opioids and a 10th category where multiple opioids were documented for the presentation. Findings: There were wide differences, up to 27-fold, between supply-adjusted rates of overdose. When considering presentations with sole opioids, the highest supply-adjusted overdose rates [per 100 000 oral morphine equivalents (OME); 95% confidence interval (CI)] were for codeine (OME = 0.078, 95% CI = 0.073–0.08) and oxycodone (OME =0.029, 95% CI = 0.027–0.030) and the lowest were for tapentadol (OME = 0.004, 95% CI = 0.003–0.006) and fentanyl (OME = 0.003, 95% CI = 0.002–0.004). These rates appeared related to availability rather than opioid potency. Most (62%) poisonings involved females. Codeine, oxycodone and tramadol were associated with younger presentations (respectively, 59.5%, 41.7% and 49.8% of presentations were 12-34 years old), and intentional self-harm (respectively 65.2%, 50.6%, and 52.8% of presentations). Relative to morphine, fentanyl [0.32 relative risk ratio (RRR)] and methadone (0.58 RRR) presentations were less likely to be coded as self-harm. Relative to morphine–buprenorphine, codeine, oxycodone and tramadol presentations were significantly more likely to be associated with the less urgent triage categories (respectively 2.18, 1.80, 1.52, 1.65 RRR). Conclusions: In Victoria, Australia, rates and characteristics of emergency department presentations for pharmaceutical opioids show distinct variations by opioid type.
AB - Background and aims: Pharmaceutical opioids are a significant contributor to the global ‘opioid crisis’, yet few studies have comprehensively distinguished between opioid types. We measured whether a range of common pharmaceutical opioids varied in their contribution to the rates and characteristics of harm in a population-wide indicator of non-fatal overdose. Design: Retrospective observational study of emergency department (ED) patient care records in the Victorian Emergency Minimum Data set (VEMD), July 2009 to June 2019. Setting: Victoria, Australia. Cases: ED presentations for non-fatal overdose related to pharmaceutical opioid use (n = 5403), where the specific pharmaceutical opioid was documented. Measurements: We compared harms across the nine individual pharmaceutical opioids most commonly sold, and considered where multiple opioids contributed to the overdose. We calculated supply-adjusted rates of ED presentations using Poisson regression and used multinomial logistic regression to compare demographic and clinical characteristics of presentations among nine distinct pharmaceutical opioids and a 10th category where multiple opioids were documented for the presentation. Findings: There were wide differences, up to 27-fold, between supply-adjusted rates of overdose. When considering presentations with sole opioids, the highest supply-adjusted overdose rates [per 100 000 oral morphine equivalents (OME); 95% confidence interval (CI)] were for codeine (OME = 0.078, 95% CI = 0.073–0.08) and oxycodone (OME =0.029, 95% CI = 0.027–0.030) and the lowest were for tapentadol (OME = 0.004, 95% CI = 0.003–0.006) and fentanyl (OME = 0.003, 95% CI = 0.002–0.004). These rates appeared related to availability rather than opioid potency. Most (62%) poisonings involved females. Codeine, oxycodone and tramadol were associated with younger presentations (respectively, 59.5%, 41.7% and 49.8% of presentations were 12-34 years old), and intentional self-harm (respectively 65.2%, 50.6%, and 52.8% of presentations). Relative to morphine, fentanyl [0.32 relative risk ratio (RRR)] and methadone (0.58 RRR) presentations were less likely to be coded as self-harm. Relative to morphine–buprenorphine, codeine, oxycodone and tramadol presentations were significantly more likely to be associated with the less urgent triage categories (respectively 2.18, 1.80, 1.52, 1.65 RRR). Conclusions: In Victoria, Australia, rates and characteristics of emergency department presentations for pharmaceutical opioids show distinct variations by opioid type.
KW - Codeine
KW - emergency department
KW - fentanyl
KW - opioids
KW - overdose
KW - oxycodone
KW - oxycodone–naloxone
KW - pharmaceutical opioids
KW - Tapentadol
KW - tramadol
UR - http://www.scopus.com/inward/record.url?scp=85114995334&partnerID=8YFLogxK
U2 - 10.1111/add.15653
DO - 10.1111/add.15653
M3 - Article
C2 - 34338377
AN - SCOPUS:85114995334
SN - 0965-2140
VL - 117
SP - 623
EP - 636
JO - Addiction
JF - Addiction
IS - 3
ER -